OREGON HEALTH & SCIENCE UNIVERSITY - TO CARRY OUT DEVELOPMENT FOR A DRUG CANDIDATE SMALL MOLECULE INHIBITOR AGAINST CHIKUNGUNYA VIRUS, AN ALPHAVIRUS THAT CAUSES DEBILITATING AND SOMETIMES LIFE-THREATENING DISEASE IN HUMANS.

On Oct 31, 2022, Department of Health and Human Services obligated $7,422,654 to OREGON HEALTH & SCIENCE UNIVERSITY for to carry out development for a drug candidate small molecule inhibitor against chikungunya virus, an alphavirus that causes debilitating and sometimes life-threatening disease in humans.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY). Competition extent: full and open competition with 10 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in PORTLAND, OR. The contract is scheduled through May 31, 2027 — approximately 9 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.